New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
- PMID: 36706749
- DOI: 10.1146/annurev-med-043021-014919
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Abstract
Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics. With the understanding of the neurobiology of obesity rapidly expanding, these emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity. This article reviews GLP-1 RAs in the treatment of obesity and previews the imminent future of nutrient-stimulated hormone-based anti-obesity therapeutics.
Keywords: GLP-1 receptor agonists; NuSH-based therapies; antiobesity medications; dual receptor agonists; nutrient-stimulated hormone-based therapies; triple receptor agonists.
Similar articles
-
Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.Chin J Nat Med. 2022 Nov;20(11):863-872. doi: 10.1016/S1875-5364(22)60196-1. Chin J Nat Med. 2022. PMID: 36427920
-
The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.Hum Reprod Update. 2019 Jul 1;25(4):504-517. doi: 10.1093/humupd/dmz019. Hum Reprod Update. 2019. PMID: 31260047 Review.
-
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221146371. doi: 10.1177/10742484221146371. J Cardiovasc Pharmacol Ther. 2022. PMID: 36546652 Review.
-
Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.Expert Opin Pharmacother. 2014 Dec;15(17):2487-500. doi: 10.1517/14656566.2014.965678. Epub 2014 Sep 26. Expert Opin Pharmacother. 2014. PMID: 25260877 Review.
-
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.Life Sci. 2022 Jan 1;288:120188. doi: 10.1016/j.lfs.2021.120188. Epub 2021 Nov 30. Life Sci. 2022. PMID: 34861287 Review.
Cited by
-
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation.J Pharm Anal. 2024 May;14(5):100917. doi: 10.1016/j.jpha.2023.12.007. Epub 2023 Dec 9. J Pharm Anal. 2024. PMID: 38799233 Free PMC article. Review.
-
Chemogenetic inhibition of the lateral hypothalamus effectively reduces food intake in rats in a translational proof-of-concept study.Sci Rep. 2024 May 18;14(1):11402. doi: 10.1038/s41598-024-62014-1. Sci Rep. 2024. PMID: 38762561 Free PMC article.
-
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists.Obes Sci Pract. 2024 May 4;10(3):e756. doi: 10.1002/osp4.756. eCollection 2024 Jun. Obes Sci Pract. 2024. PMID: 38708040 Free PMC article.
-
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.BMC Med. 2024 Feb 14;22(1):65. doi: 10.1186/s12916-024-03274-6. BMC Med. 2024. PMID: 38355513 Free PMC article.
-
Pharmacotherapy for obesity: moving towards efficacy improvement.Diabetol Metab Syndr. 2024 Jan 3;16(1):6. doi: 10.1186/s13098-023-01233-4. Diabetol Metab Syndr. 2024. PMID: 38172940 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
